Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
BioMarin Pharmaceutical Analyst Ratings and Price Targets | NASDAQ:BMRN | Benzinga
BioMarin Pharmaceutical Inc has a consensus price target of $97.59 based on the ratings of 31 analysts. The high is $140 issued by Truist Securities on September 25, 2023. The low is $65 issued by Baird on October 30, 2024. The 3 most-recent analyst ratings were released by Goldman Sachs, Citigroup, and Oppenheimer on May 5, 2025, May 2, 2025, and February 24, 2025, respectively. With an average price target of $93.33 between Goldman Sachs, Citigroup, and Oppenheimer, there's an implied 68.50% upside for BioMarin Pharmaceutical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Citigroup
Oppenheimer
Scotiabank
RBC Capital
1calculated from analyst ratings
Analyst Ratings for BioMarin Pharmaceutical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/05/2025 | Buy Now | 87.76% | Goldman Sachs | Salveen Richter51% | $124 → $104 | Maintains | Buy | Get Alert |
| 05/02/2025 | Buy Now | 40.82% | Citigroup | David Lebovitz65% | $82 → $78 | Maintains | Neutral | Get Alert |
| 02/24/2025 | Buy Now | 76.93% | Oppenheimer | Leland Gershell69% | → $98 | Upgrade | Perform → Outperform | Get Alert |
| 02/20/2025 | Buy Now | 44.43% | Scotiabank | George Farmer41% | $78 → $80 | Maintains | Sector Perform | Get Alert |
| 02/20/2025 | Buy Now | 48.04% | Citigroup | David Lebovitz65% | $81 → $82 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | 26.38% | RBC Capital | Luca Issi45% | $70 → $70 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 02/20/2025 | Buy Now | 62.48% | Cantor Fitzgerald | Olivia Brayer53% | $90 → $90 | Reiterates | Overweight → Overweight | Get Alert |
| 02/20/2025 | Buy Now | 104.01% | UBS | Eliana Merle49% | $109 → $113 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | 127.48% | Piper Sandler | Christopher Raymond55% | $122 → $126 | Maintains | Overweight | Get Alert |
| 02/20/2025 | Buy Now | 85.95% | B of A Securities | Geoff Meacham62% | $99 → $103 | Maintains | Buy | Get Alert |
| 12/12/2024 | Buy Now | 62.48% | Cantor Fitzgerald | Olivia Brayer53% | $90 → $90 | Reiterates | Overweight → Overweight | Get Alert |
| 11/15/2024 | Buy Now | 71.51% | Wolfe Research | Akash Tewari44% | → $95 | Initiates | → Outperform | Get Alert |
| 10/30/2024 | Buy Now | 46.24% | Citigroup | David Lebovitz65% | $93 → $81 | Maintains | Neutral | Get Alert |
| 10/30/2024 | Buy Now | 51.65% | Canaccord Genuity | Whitney Ijem56% | $93 → $84 | Maintains | Hold | Get Alert |
| 10/30/2024 | Buy Now | 62.48% | Cantor Fitzgerald | Olivia Brayer53% | $110 → $90 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 96.79% | JP Morgan | Jessica Fye66% | $110 → $109 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 44.43% | RBC Capital | Luca Issi45% | $80 → $80 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 10/30/2024 | Buy Now | 89.56% | Evercore ISI Group | Cory Kasimov66% | $115 → $105 | Maintains | Outperform | Get Alert |
| 10/30/2024 | Buy Now | 91.37% | UBS | Eliana Merle49% | $104 → $106 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 17.35% | Baird | Joel Beatty69% | $72 → $65 | Maintains | Neutral | Get Alert |
| 10/30/2024 | Buy Now | — | William Blair | Tim Lugo31% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/10/2024 | Buy Now | 42.63% | Raymond James | Danielle Brill43% | → $79 | Reinstates | → Outperform | Get Alert |
| 10/04/2024 | Buy Now | 44.43% | RBC Capital | Luca Issi45% | $85 → $80 | Maintains | Sector Perform | Get Alert |
| 10/04/2024 | Buy Now | 55.26% | Barclays | Gena Wang52% | $110 → $86 | Maintains | Overweight | Get Alert |
| 09/17/2024 | Buy Now | 40.82% | Scotiabank | George Farmer41% | $95 → $78 | Maintains | Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | 62.48% | Truist Securities | Joon Lee76% | $118 → $90 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 62.48% | Wells Fargo | Mohit Bansal68% | $115 → $90 | Maintains | Overweight | Get Alert |
| 09/17/2024 | Buy Now | 53.46% | RBC Capital | Luca Issi45% | $100 → $85 | Maintains | Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | 107.62% | B of A Securities | Geoff Meacham62% | $130 → $115 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 57.07% | Stifel | Paul Matteis44% | $115 → $87 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 62.48% | Bernstein | William Pickering38% | $116 → $90 | Maintains | Outperform | Get Alert |
| 09/13/2024 | Buy Now | 67.9% | Canaccord Genuity | Whitney Ijem56% | $93 → $93 | Maintains | Hold | Get Alert |
| 09/09/2024 | Buy Now | 98.59% | Cantor Fitzgerald | Olivia Brayer53% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 09/05/2024 | Buy Now | 116.65% | JP Morgan | Jessica Fye66% | $111 → $120 | Maintains | Overweight | Get Alert |
| 09/05/2024 | Buy Now | 80.54% | RBC Capital | Luca Issi45% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/05/2024 | Buy Now | 71.51% | Scotiabank | George Farmer41% | $86 → $95 | Maintains | Sector Perform | Get Alert |
| 09/05/2024 | Buy Now | 113.03% | Truist Securities | Joon Lee76% | $140 → $118 | Maintains | Buy | Get Alert |
| 09/05/2024 | Buy Now | 120.26% | Piper Sandler | Christopher Raymond55% | $107 → $122 | Maintains | Overweight | Get Alert |
| 08/27/2024 | Buy Now | 93.18% | Piper Sandler | Christopher Raymond55% | $107 → $107 | Maintains | Overweight | Get Alert |
| 08/21/2024 | Buy Now | 107.62% | Stifel | Paul Matteis44% | $112 → $115 | Maintains | Buy | Get Alert |
| 08/20/2024 | Buy Now | 98.59% | Bernstein | William Pickering38% | $94 → $110 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/06/2024 | Buy Now | 116.65% | TD Cowen | Phil Nadeau66% | $125 → $120 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 55.26% | Scotiabank | George Farmer41% | $85 → $86 | Maintains | Sector Perform | Get Alert |
| 08/06/2024 | Buy Now | 102.2% | Stifel | Paul Matteis44% | $108 → $112 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 80.54% | RBC Capital | Luca Issi45% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/06/2024 | Buy Now | 98.59% | Barclays | Gena Wang52% | $111 → $110 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 107.62% | Evercore ISI Group | Cory Kasimov66% | $113 → $115 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 98.59% | Cantor Fitzgerald | Olivia Brayer53% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 07/25/2024 | Buy Now | 60.68% | Canaccord Genuity | Whitney Ijem56% | $89 → $89 | Maintains | Hold | Get Alert |
| 07/22/2024 | Buy Now | 98.59% | Cantor Fitzgerald | Olivia Brayer53% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 06/27/2024 | Buy Now | 107.62% | Wells Fargo | Mohit Bansal68% | $110 → $115 | Maintains | Overweight | Get Alert |
| 05/17/2024 | Buy Now | 29.99% | Baird | Joel Beatty69% | $104 → $72 | Downgrade | Outperform → Neutral | Get Alert |
| 05/14/2024 | Buy Now | 104.01% | Evercore ISI Group | Cory Kasimov66% | → $113 | Initiates | → Outperform | Get Alert |
| 04/26/2024 | Buy Now | 102.2% | Morgan Stanley | Matthew Harrison61% | $115 → $112 | Maintains | Overweight | Get Alert |
| 04/26/2024 | Buy Now | 60.68% | Canaccord Genuity | Whitney Ijem56% | $91 → $89 | Maintains | Hold | Get Alert |
| 04/25/2024 | Buy Now | 98.59% | Cantor Fitzgerald | Olivia Brayer53% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 04/25/2024 | Buy Now | 64.29% | Citigroup | David Lebovitz65% | $94 → $91 | Maintains | Neutral | Get Alert |
| 04/25/2024 | Buy Now | 53.46% | Scotiabank | George Farmer41% | $83 → $85 | Maintains | Sector Perform | Get Alert |
| 04/25/2024 | Buy Now | 98.59% | Wells Fargo | Mohit Bansal68% | $100 → $110 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 64.29% | Canaccord Genuity | Whitney Ijem56% | → $91 | Reiterates | Hold → Hold | Get Alert |
| 02/23/2024 | Buy Now | 80.54% | Cantor Fitzgerald | Olivia Brayer53% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 80.54% | RBC Capital | Luca Issi45% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 02/23/2024 | Buy Now | 93.18% | Piper Sandler | Christopher Raymond55% | $115 → $107 | Maintains | Overweight | Get Alert |
| 01/30/2024 | Buy Now | 87.76% | Baird | Joel Beatty69% | $127 → $104 | Maintains | Outperform | Get Alert |
| 12/21/2023 | Buy Now | 82.34% | Stifel | Paul Matteis44% | → $101 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | Buy Now | 80.54% | RBC Capital | Luca Issi45% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/03/2023 | Buy Now | 80.54% | BMO Capital | Kostas Biliouris35% | $102 → $100 | Maintains | Outperform | Get Alert |
| 11/02/2023 | Buy Now | 107.62% | Piper Sandler | Christopher Raymond55% | $125 → $115 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 111.23% | Morgan Stanley | Matthew Harrison61% | $125 → $117 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 100.4% | Barclays | Gena Wang52% | $125 → $111 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 80.54% | Cantor Fitzgerald | Olivia Brayer53% | $120 → $100 | Maintains | Overweight | Get Alert |
| 10/23/2023 | Buy Now | 48.04% | Bernstein | William Pickering38% | → $82 | Upgrade | Underperform → Market Perform | Get Alert |
| 10/16/2023 | Buy Now | 116.65% | Cantor Fitzgerald | Olivia Brayer53% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/28/2023 | Buy Now | — | Raymond James | Laura Chico51% | — | Initiates | → Market Perform | Get Alert |
| 09/25/2023 | Buy Now | 152.75% | Truist Securities | Robyn Karnauskas54% | → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | Buy Now | 116.65% | UBS | Martin Auster55% | → $120 | Initiates | → Buy | Get Alert |
| 09/15/2023 | Buy Now | 152.75% | Truist Securities | Robyn Karnauskas54% | → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 116.65% | Cantor Fitzgerald | Olivia Brayer53% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 98.59% | Guggenheim | Debjit Chattopadhyay55% | → $110 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 80.54% | RBC Capital | Luca Issi45% | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/13/2023 | Buy Now | 116.65% | Cantor Fitzgerald | Olivia Brayer53% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | 125.67% | Morgan Stanley | Matthew Harrison61% | $129 → $125 | Maintains | Overweight | Get Alert |
| 08/01/2023 | Buy Now | 94.98% | Stifel | Paul Matteis44% | $118 → $108 | Maintains | Buy | Get Alert |
| 08/01/2023 | Buy Now | 26.38% | Wedbush | Andreas Argyrides70% | $73 → $70 | Maintains | Neutral | Get Alert |
| 08/01/2023 | Buy Now | 116.65% | Cantor Fitzgerald | Olivia Brayer53% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | 80.54% | RBC Capital | Luca Issi45% | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 07/27/2023 | Buy Now | 71.51% | Scotiabank | George Farmer41% | → $95 | Initiates | → Sector Perform | Get Alert |
| 07/21/2023 | Buy Now | 234% | B of A Securities | Geoff Meacham62% | $200 → $185 | Maintains | Buy | Get Alert |
| 07/05/2023 | Buy Now | 84.15% | BMO Capital | Kostas Biliouris35% | → $102 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/03/2023 | Buy Now | 87.76% | Canaccord Genuity | Whitney Ijem56% | $110 → $104 | Maintains | Hold | Get Alert |
| 06/30/2023 | Buy Now | 73.32% | Citigroup | David Lebowitz54% | $103 → $96 | Maintains | Neutral | Get Alert |
| 06/30/2023 | Buy Now | 129.28% | Baird | Joel Beatty69% | → $127 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | Buy Now | 31.79% | Wedbush | Andreas Argyrides70% | $69 → $73 | Maintains | Neutral | Get Alert |
| 06/30/2023 | Buy Now | 152.75% | Truist Securities | Robyn Karnauskas54% | $125 → $140 | Maintains | Buy | Get Alert |
| 06/14/2023 | Buy Now | 116.65% | Credit Suisse | Tiago Fauth47% | → $120 | Assumes | → Outperform | Get Alert |
| 04/27/2023 | Buy Now | 85.95% | Citigroup | David Lebowitz54% | $114 → $103 | Maintains | Neutral | Get Alert |
| 04/27/2023 | Buy Now | 116.65% | Guggenheim | Debjit Chattopadhyay55% | $125 → $120 | Maintains | Buy | Get Alert |
| 04/27/2023 | Buy Now | 125.67% | Piper Sandler | Christopher Raymond55% | $128 → $125 | Maintains | Overweight | Get Alert |
| 04/27/2023 | Buy Now | 80.54% | RBC Capital | Luca Issi45% | → $100 | Reiterates | → Sector Perform | Get Alert |
| 04/27/2023 | Buy Now | 24.57% | Wedbush | Andreas Argyrides70% | $74 → $69 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for BioMarin Pharmaceutical (BMRN) stock?
The latest price target for BioMarin Pharmaceutical (NASDAQ:BMRN) was reported by Goldman Sachs on May 5, 2025. The analyst firm set a price target for $104.00 expecting BMRN to rise to within 12 months (a possible 87.76% upside). 51 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioMarin Pharmaceutical (BMRN)?
The latest analyst rating for BioMarin Pharmaceutical (NASDAQ:BMRN) was provided by Goldman Sachs, and BioMarin Pharmaceutical maintained their buy rating.
When was the last upgrade for BioMarin Pharmaceutical (BMRN)?
The last upgrade for BioMarin Pharmaceutical Inc happened on February 24, 2025 when Oppenheimer raised their price target to $98. Oppenheimer previously had a perform for BioMarin Pharmaceutical Inc.
When was the last downgrade for BioMarin Pharmaceutical (BMRN)?
The last downgrade for BioMarin Pharmaceutical Inc happened on October 30, 2024 when William Blair changed their price target from N/A to N/A for BioMarin Pharmaceutical Inc.
When is the next analyst rating going to be posted or updated for BioMarin Pharmaceutical (BMRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioMarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioMarin Pharmaceutical was filed on May 5, 2025 so you should expect the next rating to be made available sometime around May 5, 2026.
Is the Analyst Rating BioMarin Pharmaceutical (BMRN) correct?
While ratings are subjective and will change, the latest BioMarin Pharmaceutical (BMRN) rating was a maintained with a price target of $124.00 to $104.00. The current price BioMarin Pharmaceutical (BMRN) is trading at is $55.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
